Table 3. Assessed adverse events by the UKU Side Effect Rating Scale for 78 healthy first degree relatives of patients with a history of major depressive disorder following four weeks of intervention by escitalopram 10 mg (N = 39) or placebo (N = 39) in the AGENDA trial.
Adverse events | Escitalopram N (%) | Placebo N (%) | p (χ2) |
Restlessness | 6 (15) | 9 (23) | 0.39 |
Insomnia | 2 (5) | 9 (23) | 0.02* |
Tremor | 1 (3) | 1 (3) | 1.00 |
Nausea | 4 (10) | 4 (10) | 1.00 |
Diarrhoea | 4 (10) | 1 (3) | 0.17 |
Sweating | 6 (15) | 4 (10) | 0.50 |
Less libido | 7 (18) | 2 (5) | 0.08 |
Erective dysfunction (men) | 5 (13) | 1 (3) | 0.09 |
Ejaculating problems (men) | 11 (28) | 1 (3) | 0.002* |
Orgasmic dysfunction | 11 (28) | 0 (0) | 0* |
Headache | 1 (3) | 1 (3) | 1.00 |